BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Wave Life Sciences readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Wave Life Sciences's drugs run\, 
 from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06405633-10846@assetmemo.bio
DTSTAMP:20261121T004525Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:WVE-006: Phase 1/2 readout est. (NCT06405633)
DESCRIPTION:WVE-006\, phase 1/2\, Alpha-1 Antitrypsin Deficiency.\nStudy: A
  Phase 1b/2a\, Open-label Single Ascending Doses and Multiple Ascending Do
 ses Study in Participants With Pi*ZZ AATD\nEstimated primary completion: S
 eptember 2027. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/wve-00
 6#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06
 405633
URL:https://assetmemo.bio/drug/wve-006#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06842186-270@assetmemo.bio
DTSTAMP:20261121T004525Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:WVE-007: Phase 1/2 readout est. (NCT06842186)
DESCRIPTION:WVE-007\, phase 1/2\, Obesity.\nStudy: A Phase 1/2a Study of WV
 E-007 in Adults Living With Overweight or Obesity\nEstimated primary compl
 etion: December 2027. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /wve-007#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT06842186
URL:https://assetmemo.bio/drug/wve-007#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07209332-10847@assetmemo.bio
DTSTAMP:20261121T004525Z
DTSTART;VALUE=DATE:20290331
DTEND;VALUE=DATE:20290401
SUMMARY:Bampidirsen: Phase 2 readout est. (NCT07209332)
DESCRIPTION:Bampidirsen\, phase 2\, Duchenne Muscular Dystrophy.\nStudy: Op
 en-Label Extension Study of WVE-N531 in Patients With Duchenne Muscular Dy
 strophy\nEstimated primary completion: March 2029. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/bampidirsen#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT07209332
URL:https://assetmemo.bio/drug/bampidirsen#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
